Apr. 9, 2003 CHAPEL HILL -- A study led by scientists at the University of North Carolina at Chapel Hill offers the first molecular explanation of how the body metabolizes and detoxifies cocaine and heroin.
"We show for the first time how humans initiate the breakdown and clearance of these dangerous narcotics," said Dr. Matthew R. Redinbo, assistant professor in the department of chemistry, and in the School of Medicine's department of biochemistry and biophysics.
"This work also has two potential applications. First, our results can be used to generate an efficient treatment for cocaine overdose. Second, the same system we describe can be engineered to detoxify chemical weapons, including sarin, soman, tabun and VX gases."
A report of the study, published online Monday (April 7) in Nature Structural Biology, presents the first crystal structure of the protein human carboxylesterase 1, or hCE1.
The protein, an enzyme, is a broad-spectrum bioscavenger found throughout the body - in the liver, small intestine, kidney, lungs, testes and scavenger cells. It also circulates to a lesser extent in human blood plasma.
In their report, Redinbo and his group describe how hCE1 is responsible for metabolizing the first step of cocaine breakdown in the body and the first two steps of heroin breakdown. The researchers determined the crystal structure of the enzyme in complexes with analogues of cocaine and heroin.
They found the enzyme could bind to two cocaine molecules simultaneously, but that it specifically generates the primary metabolic breakdown product (metabolite) of cocaine. This indicates that the enzyme holds "significant promise in the treatment of acute cocaine overdose," the report said.
"We need to engineer a more active form of the enzyme that is specific for cocaine. We can do this by generating a small number of changes in the amino acid sequence that would increase the metabolic efficiency," Redinbo said.
When injected into an overdose victim, the enzyme could help metabolize the cocaine before it became toxic, he said.
Heroin poses another problem. It has no activity on its own. "It needs to be broken down a little in the body to make morphine," Redinbo said. "It's morphine's activity, hitting opioid receptors in the brain, that provides the feeling of complacency and peace associated with heroin use."
In terms of using hCE1 against chemical weapons, Redinbo said the U.S. military is aggressively seeking to develop the enzyme as a battlefield prophylactic that could be used to detoxify sarin, soman, tabun and VX gases. Chemically, these nerve agents are organophosphate poisons, similar in structure to agricultural weed control chemicals.
"Without the crystal structure, they have been making educated guesses as to where to make changes in the enzyme that would increase its efficiency in detoxifying these agents," said Redinbo. "Now, knowledge of the crystal structure takes much of the guesswork out of identifying the most effective modifications."
The military's idea is to inject its people with protective enzymes prior to battle, he said; these enzymes have a long serum half-life and could offer several days of protection.
"These chemical weapons kill by impacting nerve endings throughout the body, including in the respiratory system. One could inject or inhale the protectant, and it's not likely to cause an immune reaction because it's a human protein," Redinbo said.
It also appears that the enzyme plays a role in cholesterol metabolism - namely, cholesterol transport into and out of the liver. "Its primary evolutionary role may be this function," said study lead author Sompop Bencharit, a chemistry graduate student in Redinbo's laboratory.
"Our crystal structures of hCE1 will enable the development of highly selective and efficient forms of the enzyme for use in a variety of civilian and military settings," the report said. "The engineering of novel hCE1 enzymes with improved catalytic power toward cocaine or organophosphate poisons is currently in progress."
The National Cancer Institute, a component of the National Institutes of Health, supported the research, which involved a close collaboration with Dr. Philip Potter, an associate member at St. Jude Children's Research Hospital in Memphis, Tenn.
Other social bookmarking and sharing tools:
The above story is reprinted from materials provided by University Of North Carolina School Of Medicine.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Note: If no author is given, the source is cited instead.